WASHINGTON – In a decision with important implications for the evolving field of personalized medicine, a unanimous U.S. Supreme Court on March 20 invalidated two patents on a diagnostic test used in connection with the treatment of autoimmune diseases.
Mayo Collaborative Services v. Prometheus Laboratories Inc., 10-1150, pitted doctors and researchers against biotechnology and pharmaceutical companies in the ongoing debate over what is patentable subject matter.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
